10 most important contemporary challenges in the management of SLE

被引:56
作者
Felten, Renaud [1 ,2 ]
Sagez, Flora [1 ,2 ]
Gavand, Pierre-Edouard [2 ,3 ]
Martin, Thierry [2 ,3 ]
Korganow, Anne-Sophie [2 ,3 ]
Sordet, Christelle [1 ,2 ]
Javier, Rose-Marie [1 ,2 ]
Soulas-Sprauel, Pauline [2 ,3 ]
Riviere, Marianne [4 ]
Scher, Florence [5 ]
Poindron, Vincent [2 ,3 ]
Guffroy, Aurelien [2 ,3 ]
Arnaud, Laurent [1 ,2 ]
机构
[1] Univ Strasbourg, Hop Univ Strasbourg, Serv Rhumatol, Strasbourg, France
[2] Ctr Natl References Malad Syst & Autoimmunes Rare, Strasbourg, France
[3] Univ Strasbourg, Hop Univ Strasbourg, Serv Immunol Clin, Strasbourg, France
[4] Assoc Francaise Lupus & Autres Malad Autoimmunes, Strasbourg, France
[5] Hop Univ Strasbourg, Serv Pharm Sterilisat, Strasbourg, France
来源
LUPUS SCIENCE & MEDICINE | 2019年 / 6卷 / 01期
关键词
SYSTEMIC-LUPUS-ERYTHEMATOSUS; DISEASE-ACTIVITY INDEX; BONE-MINERAL DENSITY; RISK-FACTORS; PHYSICAL-ACTIVITY; CUTANEOUS LUPUS; GENETIC-BASIS; RECOMMENDATIONS; PREVALENCE; PATHWAYS;
D O I
10.1136/lupus-2018-000303
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
From a 1-year survival of less than 50% before the discovery of glucocorticoids to over 90% at 10 years in most dedicated centres, the spectrum of SLE has profoundly evolved. Despite this improvement, several major challenges currently remain. The aim of this review is to analyse what are, according to us, the 10 most important contemporary challenges in the management of SLE. Among those are the need to treat to target to favour disease remission (or low disease activity), limit the use of glucocorticoids, derive more comprehensive tools for the evaluation of disease activity, develop more effective drugs (yielding successful trials), dissect the heterogeneity of the disease both at the molecular and genetic levels, identify relevant biomarkers for individualised treatment, manage fertility and pregnancy, tackle comorbidities such as cardiovascular risk, the prevention of infections and osteoporosis, improve the network of care (from the patients' perspective), and favour a holistic approach (integrating fatigue, adherence to treatment, physical activity). Altogether, these 10 contemporary challenges in SLE may be considered as a roadmap for those involved in the daily care of patients with SLE, as well as for researchers who may wish to contribute to an improved management of this rare and complex disease.
引用
收藏
页数:6
相关论文
共 49 条
[1]  
Ahn Grace E, 2012, Int J Clin Rheumtol, V7, P217
[2]   The CLASI (Cutaneous Lupus Erythematosus Disease Area and Severity Index): An outcome instrument for cutaneous lupus erythematosus [J].
Albrecht, J ;
Taylor, L ;
Berlin, JA ;
Dulay, S ;
Ang, G ;
Fakharzadeh, S ;
Kantor, J ;
Kim, E ;
Militello, G ;
McGinnis, K ;
Richardson, S ;
Treat, J ;
Vittorio, C ;
Van Voorhees, A ;
Werth, VP .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2005, 125 (05) :889-894
[3]   Independent association of glucocorticoids with damage accrual in SLE [J].
Apostolopoulos, Diane ;
Kandane-Rathnayake, Rangi ;
Raghunath, Sudha ;
Hoi, Alberta ;
Nikpour, Mandana ;
Morand, Eric F. .
LUPUS SCIENCE & MEDICINE, 2016, 3 (01)
[4]   Mycophenolate Mofetil versus Cyclophosphamide for Induction Treatment of Lupus Nephritis [J].
Appel, Gerald B. ;
Contreras, Gabriel ;
Dooley, Mary Anne ;
Ginzler, Ellen M. ;
Isenberg, David ;
Jayne, David ;
Li, Lei-Shi ;
Mysler, Eduardo ;
Sanchez-Guerrero, Jorge ;
Solomons, Neil ;
Wofsy, David .
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2009, 20 (05) :1103-1112
[5]   Screening and management of cardiovascular risk factors in systemic lupus erythematosus: Recommendations for clinical practice based on the literature and expert opinion [J].
Arnaud, L. ;
Mathian, A. ;
Adoue, D. ;
Bader-Meunier, B. ;
Baudouin, V. ;
Belizna, C. ;
Bonnotte, B. ;
Boumedine, F. ;
Chaib, A. ;
Chauchard, M. ;
Chiche, L. ;
Daugas, E. ;
Ghali, A. ;
Gobert, P. ;
Gondran, G. ;
Guettrot-Imbert, G. ;
Hachulla, E. ;
Hamidou, M. ;
Haroche, J. ;
Hervier, B. ;
Hummel, A. ;
Jourde-Chiche, N. ;
Korganow, A-S ;
Kwon, T. ;
Le Guern, V. ;
Le Quellec, A. ;
Limal, N. ;
Magy-Bertrand, N. ;
Marianetti-Guingel, P. ;
Martin, T. ;
Silva, N. Martin ;
Meyer, O. ;
Miyara, M. ;
Morell-Dubois, S. ;
Ninet, J. ;
Papo, T. ;
Pennaforte, J-L ;
Polomat, K. ;
Pourrat, J. ;
Queyrel, V. ;
Raymond, I. ;
Remy, P. ;
Sacre, K. ;
Schmidt, J. ;
Sibilia, J. ;
Viallard, J-F ;
Brabant, A. Viau ;
Wahl, D. ;
Bruckert, E. ;
Amoura, Z. .
REVUE DE MEDECINE INTERNE, 2015, 36 (06) :372-380
[6]   Prevalence and incidence of systemic lupus erythematosus in France: A 2010 nation-wide population-based study [J].
Arnaud, Laurent ;
Fagot, Jean-Paul ;
Mathian, Alexis ;
Paita, Michel ;
Fagot-Campagna, Anne ;
Amoura, Zahir .
AUTOIMMUNITY REVIEWS, 2014, 13 (11) :1082-1089
[7]   Type I interferon in systemic lupus erythematosus and other autoimmune diseases [J].
Banchereau, Jacques ;
Pascual, Virginia .
IMMUNITY, 2006, 25 (03) :383-392
[8]   Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients [J].
Banchereau, Romain ;
Hong, Seunghee ;
Cantarel, Brandi ;
Baldwin, Nicole ;
Baisch, Jeanine ;
Edens, Michelle ;
Cepika, Alma-Martina ;
Acs, Peter ;
Turner, Jacob ;
Anguiano, Esperanza ;
Vinod, Parvathi ;
Kahn, Shaheen ;
Obermoser, Gerlinde ;
Blankenship, Derek ;
Wakeland, Edward ;
Nassi, Lorien ;
Gotte, Alisa ;
Punaro, Marilynn ;
Liu, Yong-Jun ;
Banchereau, Jacques ;
Rossello-Urgell, Jose ;
Wright, Tracey ;
Pascual, Virginia .
CELL, 2016, 165 (03) :551-565
[9]   DERIVATION OF THE SLEDAI - A DISEASE-ACTIVITY INDEX FOR LUPUS PATIENTS [J].
BOMBARDIER, C ;
GLADMAN, DD ;
UROWITZ, MB ;
CARON, D ;
CHANG, CH .
ARTHRITIS AND RHEUMATISM, 1992, 35 (06) :630-640
[10]   Bone Disease in Connective Tissue Disease/Systemic Lupus Erythematosus [J].
Bultink, Irene E. M. .
CALCIFIED TISSUE INTERNATIONAL, 2018, 102 (05) :575-591